Home・Listă Acțiuni・TransMedics Group Inc

TransMedics Group Inc

Închisă

SectorSănătate

80.5 -1.38

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

78.31

Maxim

81.92

Indicatori cheie
By Trading Economics
Venit	-98M 7.3M
Vânzări	13M 174M
P/E Medie Sector	16.998 64.641
EPS	0.3
Marjă de profit	4.206
Angajați	898
EBITDA	-4.9M 28M

Recomandări
By TipRanks
Recomandări	Cumpărare
Prognoză pe 12 luni	+41.02% upside

Dividende
By Acuity
Următoarele câștiguri	4 aug. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-786M 2.6B
Deschiderea anterioară	81.88
Închiderea anterioară	80.5

Sentimentul știrilor

By Acuity

65%

35%

289 / 340 Clasament în Healthcare

TransMedics Group Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

3 aug. 2026, 19:51 UTC

Social Media

News

TransMedics Group Inc. shares are rising, despite an analyst downgrade to a $106 price target from $142, amid positive social media discussions.

30 iul. 2026, 19:03 UTC

Transmedics Group Inc shares are lower during Thursday's session, with no specific news identified. Broader market uncertainty may be influencing the decline.

29 iul. 2026, 23:36 UTC

Transmedics Group Inc. shares are lower in after-market trading, reflecting broader market volatility amid rising interest rates and geopolitical tensions.

28 iul. 2026, 19:46 UTC

Transmedics Group Inc shares are higher today, advancing since Monday. The stock peaked earlier but pulled back from a session high.

27 iul. 2026, 15:16 UTC

Social Media

News

Transmedics Group Inc is higher today amid social media discussions on its undervaluation and expectations for significant profit by 2028.

24 iul. 2026, 20:02 UTC

Social Media

Transmedics Group Inc gains amid positive feedback from Jefferies on its technology and growth prospects, aligning with strength in the Health Care Equipment sector.

22 iul. 2026, 19:46 UTC

Transmedics Group Inc shares are lower today, reflecting ongoing declines. The stock's volatility coincides with rising crude oil prices amid geopolitical tensions.

21 iul. 2026, 14:36 UTC

Social Media

Transmedics Group's shares are higher today following the first lung transplant using its OCS warm-perfusion device, enhancing organ preservation and clinical outcomes.

20 iul. 2026, 12:26 UTC

Social Media

TransMedics Group Inc shares are higher in pre-market trading amid strong operational growth, with flights exceeding 36 per day and projected revenue of $3 billion by 2032.

Comparație

Modificare preț

TransMedics Group Inc Așteptări

Obiectiv de preț

By TipRanks

41.02% sus

Prognoză pe 12 luni

Medie 115 USD 41.02%

Maxim 175 USD

Minim 80 USD

În baza a 10 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruTransMedics Group Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

10 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 10 analiști care au acordat evaluări ale acțiunilor TransMedics Group Inc - Dist în ultimele 3 luni.

Sentiment

By Acuity

289 / 340 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre TransMedics Group Inc

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.